メサラミン(リアルダ)の世界市場規模・現状・予測2021年-2027年

QYResearchが発行した調査報告書(QY21APR3709)
◆英語タイトル:Global Mesalamine (Lialda) Market Size, Status and Forecast 2021-2027
◆商品コード:QY21APR3709
◆発行会社(リサーチ会社):QYResearch
◆発行日:2021年4月
◆ページ数:94
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥526,500見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥789,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査資料では、メサラミン(リアルダ)の世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(浣腸、錠剤、座薬、その他)、用途別市場規模(大腸炎、クローン病、直腸炎、下痢性過敏性腸症候群、憩室炎、その他)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。
・市場概要
・メサラミン(リアルダ)の市場動向
・企業の競争状況、市場シェア
・メサラミン(リアルダ)の種類別市場規模(浣腸、錠剤、座薬、その他)
・メサラミン(リアルダ)の用途別市場規模(大腸炎、クローン病、直腸炎、下痢性過敏性腸症候群、憩室炎、その他)
・メサラミン(リアルダ)の北米市場規模2016-2027(アメリカ、カナダ)
・メサラミン(リアルダ)の欧州市場規模2016-2027(ドイツ、フランス、イギリス等)
・メサラミン(リアルダ)のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・メサラミン(リアルダ)の中南米市場規模2016-2027(メキシコ、ブラジル)
・メサラミン(リアルダ)の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(Dr.Falk Pharma、Ferring、Ethypharm Pharmaceutical、Shanghai Pharmaceutical、Tillotts Pharma、Holy Stone Healthcare、Giuliani、Zeria、Lupin、Heilongjiang Tianhong Pharmaceutical、HENGCHENG PHARMACEUTICAL、KWAI FA Pharmaceutical Group)
・結論
【レポートの概要】

An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease 2. It is considered to be the active moiety of sulphasalazine. (From Martindale, The Extra Pharmacopoeia, 30th ed) Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent.

Market Analysis and Insights: Global Mesalamine (Lialda) Market
The global Mesalamine (Lialda) market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Mesalamine (Lialda) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Mesalamine (Lialda) market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Mesalamine (Lialda) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Mesalamine (Lialda) market.

Global Mesalamine (Lialda) Scope and Market Size
Mesalamine (Lialda) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Mesalamine (Lialda) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Enemas
Tablets
Suppositories
Other

Segment by Application
Colitis
Crohn’s Disease
Proctitis
Diarrheal Irritable Bowel Syndrome
Diverticulitis
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Dr.Falk Pharma
Ferring
Ethypharm Pharmaceutical
Shanghai Pharmaceutical
Tillotts Pharma
Holy Stone Healthcare
Giuliani
Zeria
Lupin
Heilongjiang Tianhong Pharmaceutical

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Mesalamine (Lialda) Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Enemas
1.2.3 Tablets
1.2.4 Suppositories
1.2.5 Other
1.3 Market by Application
1.3.1 Global Mesalamine (Lialda) Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Colitis
1.3.3 Crohn’s Disease
1.3.4 Proctitis
1.3.5 Diarrheal Irritable Bowel Syndrome
1.3.6 Diverticulitis
1.3.7 Other
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Mesalamine (Lialda) Market Perspective (2016-2027)
2.2 Mesalamine (Lialda) Growth Trends by Regions
2.2.1 Mesalamine (Lialda) Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Mesalamine (Lialda) Historic Market Share by Regions (2016-2021)
2.2.3 Mesalamine (Lialda) Forecasted Market Size by Regions (2022-2027)
2.3 Mesalamine (Lialda) Industry Dynamic
2.3.1 Mesalamine (Lialda) Market Trends
2.3.2 Mesalamine (Lialda) Market Drivers
2.3.3 Mesalamine (Lialda) Market Challenges
2.3.4 Mesalamine (Lialda) Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Mesalamine (Lialda) Players by Revenue
3.1.1 Global Top Mesalamine (Lialda) Players by Revenue (2016-2021)
3.1.2 Global Mesalamine (Lialda) Revenue Market Share by Players (2016-2021)
3.2 Global Mesalamine (Lialda) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Mesalamine (Lialda) Revenue
3.4 Global Mesalamine (Lialda) Market Concentration Ratio
3.4.1 Global Mesalamine (Lialda) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Mesalamine (Lialda) Revenue in 2020
3.5 Mesalamine (Lialda) Key Players Head office and Area Served
3.6 Key Players Mesalamine (Lialda) Product Solution and Service
3.7 Date of Enter into Mesalamine (Lialda) Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Mesalamine (Lialda) Breakdown Data by Type
4.1 Global Mesalamine (Lialda) Historic Market Size by Type (2016-2021)
4.2 Global Mesalamine (Lialda) Forecasted Market Size by Type (2022-2027)

5 Mesalamine (Lialda) Breakdown Data by Application
5.1 Global Mesalamine (Lialda) Historic Market Size by Application (2016-2021)
5.2 Global Mesalamine (Lialda) Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Mesalamine (Lialda) Market Size (2016-2027)
6.2 North America Mesalamine (Lialda) Market Size by Type
6.2.1 North America Mesalamine (Lialda) Market Size by Type (2016-2021)
6.2.2 North America Mesalamine (Lialda) Market Size by Type (2022-2027)
6.2.3 North America Mesalamine (Lialda) Market Size by Type (2016-2027)
6.3 North America Mesalamine (Lialda) Market Size by Application
6.3.1 North America Mesalamine (Lialda) Market Size by Application (2016-2021)
6.3.2 North America Mesalamine (Lialda) Market Size by Application (2022-2027)
6.3.3 North America Mesalamine (Lialda) Market Size by Application (2016-2027)
6.4 North America Mesalamine (Lialda) Market Size by Country
6.4.1 North America Mesalamine (Lialda) Market Size by Country (2016-2021)
6.4.2 North America Mesalamine (Lialda) Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Mesalamine (Lialda) Market Size (2016-2027)
7.2 Europe Mesalamine (Lialda) Market Size by Type
7.2.1 Europe Mesalamine (Lialda) Market Size by Type (2016-2021)
7.2.2 Europe Mesalamine (Lialda) Market Size by Type (2022-2027)
7.2.3 Europe Mesalamine (Lialda) Market Size by Type (2016-2027)
7.3 Europe Mesalamine (Lialda) Market Size by Application
7.3.1 Europe Mesalamine (Lialda) Market Size by Application (2016-2021)
7.3.2 Europe Mesalamine (Lialda) Market Size by Application (2022-2027)
7.3.3 Europe Mesalamine (Lialda) Market Size by Application (2016-2027)
7.4 Europe Mesalamine (Lialda) Market Size by Country
7.4.1 Europe Mesalamine (Lialda) Market Size by Country (2016-2021)
7.4.2 Europe Mesalamine (Lialda) Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Mesalamine (Lialda) Market Size (2016-2027)
8.2 Asia-Pacific Mesalamine (Lialda) Market Size by Type
8.2.1 Asia-Pacific Mesalamine (Lialda) Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Mesalamine (Lialda) Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Mesalamine (Lialda) Market Size by Type (2016-2027)
8.3 Asia-Pacific Mesalamine (Lialda) Market Size by Application
8.3.1 Asia-Pacific Mesalamine (Lialda) Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Mesalamine (Lialda) Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Mesalamine (Lialda) Market Size by Application (2016-2027)
8.4 Asia-Pacific Mesalamine (Lialda) Market Size by Region
8.4.1 Asia-Pacific Mesalamine (Lialda) Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Mesalamine (Lialda) Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Mesalamine (Lialda) Market Size (2016-2027)
9.2 Latin America Mesalamine (Lialda) Market Size by Type
9.2.1 Latin America Mesalamine (Lialda) Market Size by Type (2016-2021)
9.2.2 Latin America Mesalamine (Lialda) Market Size by Type (2022-2027)
9.2.3 Latin America Mesalamine (Lialda) Market Size by Type (2016-2027)
9.3 Latin America Mesalamine (Lialda) Market Size by Application
9.3.1 Latin America Mesalamine (Lialda) Market Size by Application (2016-2021)
9.3.2 Latin America Mesalamine (Lialda) Market Size by Application (2022-2027)
9.3.3 Latin America Mesalamine (Lialda) Market Size by Application (2016-2027)
9.4 Latin America Mesalamine (Lialda) Market Size by Country
9.4.1 Latin America Mesalamine (Lialda) Market Size by Country (2016-2021)
9.4.2 Latin America Mesalamine (Lialda) Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Mesalamine (Lialda) Market Size (2016-2027)
10.2 Middle East & Africa Mesalamine (Lialda) Market Size by Type
10.2.1 Middle East & Africa Mesalamine (Lialda) Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Mesalamine (Lialda) Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Mesalamine (Lialda) Market Size by Type (2016-2027)
10.3 Middle East & Africa Mesalamine (Lialda) Market Size by Application
10.3.1 Middle East & Africa Mesalamine (Lialda) Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Mesalamine (Lialda) Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Mesalamine (Lialda) Market Size by Application (2016-2027)
10.4 Middle East & Africa Mesalamine (Lialda) Market Size by Country
10.4.1 Middle East & Africa Mesalamine (Lialda) Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Mesalamine (Lialda) Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Dr.Falk Pharma
11.1.1 Dr.Falk Pharma Company Details
11.1.2 Dr.Falk Pharma Business Overview
11.1.3 Dr.Falk Pharma Mesalamine (Lialda) Introduction
11.1.4 Dr.Falk Pharma Revenue in Mesalamine (Lialda) Business (2016-2021)
11.1.5 Dr.Falk Pharma Recent Development
11.2 Ferring
11.2.1 Ferring Company Details
11.2.2 Ferring Business Overview
11.2.3 Ferring Mesalamine (Lialda) Introduction
11.2.4 Ferring Revenue in Mesalamine (Lialda) Business (2016-2021)
11.2.5 Ferring Recent Development
11.3 Ethypharm Pharmaceutical
11.3.1 Ethypharm Pharmaceutical Company Details
11.3.2 Ethypharm Pharmaceutical Business Overview
11.3.3 Ethypharm Pharmaceutical Mesalamine (Lialda) Introduction
11.3.4 Ethypharm Pharmaceutical Revenue in Mesalamine (Lialda) Business (2016-2021)
11.3.5 Ethypharm Pharmaceutical Recent Development
11.4 Shanghai Pharmaceutical
11.4.1 Shanghai Pharmaceutical Company Details
11.4.2 Shanghai Pharmaceutical Business Overview
11.4.3 Shanghai Pharmaceutical Mesalamine (Lialda) Introduction
11.4.4 Shanghai Pharmaceutical Revenue in Mesalamine (Lialda) Business (2016-2021)
11.4.5 Shanghai Pharmaceutical Recent Development
11.5 Tillotts Pharma
11.5.1 Tillotts Pharma Company Details
11.5.2 Tillotts Pharma Business Overview
11.5.3 Tillotts Pharma Mesalamine (Lialda) Introduction
11.5.4 Tillotts Pharma Revenue in Mesalamine (Lialda) Business (2016-2021)
11.5.5 Tillotts Pharma Recent Development
11.6 Holy Stone Healthcare
11.6.1 Holy Stone Healthcare Company Details
11.6.2 Holy Stone Healthcare Business Overview
11.6.3 Holy Stone Healthcare Mesalamine (Lialda) Introduction
11.6.4 Holy Stone Healthcare Revenue in Mesalamine (Lialda) Business (2016-2021)
11.6.5 Holy Stone Healthcare Recent Development
11.7 Giuliani
11.7.1 Giuliani Company Details
11.7.2 Giuliani Business Overview
11.7.3 Giuliani Mesalamine (Lialda) Introduction
11.7.4 Giuliani Revenue in Mesalamine (Lialda) Business (2016-2021)
11.7.5 Giuliani Recent Development
11.8 Zeria
11.8.1 Zeria Company Details
11.8.2 Zeria Business Overview
11.8.3 Zeria Mesalamine (Lialda) Introduction
11.8.4 Zeria Revenue in Mesalamine (Lialda) Business (2016-2021)
11.8.5 Zeria Recent Development
11.9 Lupin
11.9.1 Lupin Company Details
11.9.2 Lupin Business Overview
11.9.3 Lupin Mesalamine (Lialda) Introduction
11.9.4 Lupin Revenue in Mesalamine (Lialda) Business (2016-2021)
11.9.5 Lupin Recent Development
11.10 Heilongjiang Tianhong Pharmaceutical
11.10.1 Heilongjiang Tianhong Pharmaceutical Company Details
11.10.2 Heilongjiang Tianhong Pharmaceutical Business Overview
11.10.3 Heilongjiang Tianhong Pharmaceutical Mesalamine (Lialda) Introduction
11.10.4 Heilongjiang Tianhong Pharmaceutical Revenue in Mesalamine (Lialda) Business (2016-2021)
11.10.5 Heilongjiang Tianhong Pharmaceutical Recent Development
11.11 HENGCHENG PHARMACEUTICAL
11.11.1 HENGCHENG PHARMACEUTICAL Company Details
11.11.2 HENGCHENG PHARMACEUTICAL Business Overview
11.11.3 HENGCHENG PHARMACEUTICAL Mesalamine (Lialda) Introduction
11.11.4 HENGCHENG PHARMACEUTICAL Revenue in Mesalamine (Lialda) Business (2016-2021)
11.11.5 HENGCHENG PHARMACEUTICAL Recent Development
11.12 KWAI FA Pharmaceutical Group
11.12.1 KWAI FA Pharmaceutical Group Company Details
11.12.2 KWAI FA Pharmaceutical Group Business Overview
11.12.3 KWAI FA Pharmaceutical Group Mesalamine (Lialda) Introduction
11.12.4 KWAI FA Pharmaceutical Group Revenue in Mesalamine (Lialda) Business (2016-2021)
11.12.5 KWAI FA Pharmaceutical Group Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details



【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ メサラミン(リアルダ)の世界市場規模・現状・予測2021年-2027年(Global Mesalamine (Lialda) Market Size, Status and Forecast 2021-2027)]についてメールでお問い合わせはこちらでお願いします。